vs
CoStar Group（CSGP）与豪洛捷（HOLX）财务数据对比。点击上方公司名可切换其他公司
豪洛捷的季度营收约是CoStar Group的1.2倍（$1.0B vs $899.9M），豪洛捷净利率更高（17.1% vs 5.2%，领先11.9%），CoStar Group同比增速更快（26.9% vs 2.5%），豪洛捷自由现金流更多（$215.2M vs $101.3M），过去两年CoStar Group的营收复合增速更高（17.1% vs 1.5%）
CoStar Group是1987年成立的美国商业地产服务商，总部位于弗吉尼亚州阿灵顿，业务覆盖北美、欧洲地区，为商业地产行业提供信息、分析及营销解决方案，旗下运营CoStar线上数据库、新闻网站及Apartments.com、Homes.com等多个线上平台。
豪洛捷是一家总部位于美国的医疗科技企业，核心业务聚焦女性健康领域，旗下产品涵盖诊断、外科手术及医学影像类专业医疗设备，为全球各地的医疗场景提供优质技术与产品支持。
CSGP vs HOLX — 直观对比
营收规模更大
HOLX
是对方的1.2倍
$899.9M
营收增速更快
CSGP
高出24.3%
2.5%
净利率更高
HOLX
高出11.9%
5.2%
自由现金流更多
HOLX
多$113.9M
$101.3M
两年增速更快
CSGP
近两年复合增速
1.5%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $899.9M | $1.0B |
| 净利润 | $46.5M | $179.1M |
| 毛利率 | 78.6% | 56.0% |
| 营业利润率 | 5.5% | 22.6% |
| 净利率 | 5.2% | 17.1% |
| 营收同比 | 26.9% | 2.5% |
| 净利润同比 | -22.2% | -10.9% |
| 每股收益（稀释后） | $0.12 | $0.79 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CSGPHOLX
| Q4 25 | $899.9M | $1.0B | ||
| Q3 25 | $833.6M | $1.0B | ||
| Q2 25 | $781.3M | $1.0B | ||
| Q1 25 | $732.2M | $1.0B | ||
| Q4 24 | $709.4M | $1.0B | ||
| Q3 24 | $692.6M | $988.0M | ||
| Q2 24 | $677.8M | $1.0B | ||
| Q1 24 | $656.4M | $1.0B |
净利润CSGPHOLX
| Q4 25 | $46.5M | $179.1M | ||
| Q3 25 | $-30.9M | $187.2M | ||
| Q2 25 | $6.2M | $194.9M | ||
| Q1 25 | $-14.8M | $-17.4M | ||
| Q4 24 | $59.8M | $201.0M | ||
| Q3 24 | $53.0M | $178.6M | ||
| Q2 24 | $19.2M | $194.5M | ||
| Q1 24 | $6.7M | $169.9M |
毛利率CSGPHOLX
| Q4 25 | 78.6% | 56.0% | ||
| Q3 25 | 79.3% | 55.6% | ||
| Q2 25 | 78.5% | 56.3% | ||
| Q1 25 | 79.1% | 37.5% | ||
| Q4 24 | 80.1% | 56.8% | ||
| Q3 24 | 79.7% | 56.4% | ||
| Q2 24 | 80.0% | 55.4% | ||
| Q1 24 | 78.5% | 53.3% |
营业利润率CSGPHOLX
| Q4 25 | 5.5% | 22.6% | ||
| Q3 25 | -6.1% | 22.6% | ||
| Q2 25 | -3.5% | 24.9% | ||
| Q1 25 | -5.8% | -0.7% | ||
| Q4 24 | 5.6% | 22.5% | ||
| Q3 24 | 3.4% | 23.3% | ||
| Q2 24 | -2.4% | 24.1% | ||
| Q1 24 | -6.5% | 20.7% |
净利率CSGPHOLX
| Q4 25 | 5.2% | 17.1% | ||
| Q3 25 | -3.7% | 17.8% | ||
| Q2 25 | 0.8% | 19.0% | ||
| Q1 25 | -2.0% | -1.7% | ||
| Q4 24 | 8.4% | 19.7% | ||
| Q3 24 | 7.7% | 18.1% | ||
| Q2 24 | 2.8% | 19.2% | ||
| Q1 24 | 1.0% | 16.7% |
每股收益（稀释后）CSGPHOLX
| Q4 25 | $0.12 | $0.79 | ||
| Q3 25 | $-0.07 | $0.84 | ||
| Q2 25 | $0.01 | $0.86 | ||
| Q1 25 | $-0.04 | $-0.08 | ||
| Q4 24 | $0.14 | $0.87 | ||
| Q3 24 | $0.13 | $0.75 | ||
| Q2 24 | $0.05 | $0.82 | ||
| Q1 24 | $0.02 | $0.72 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.6B | $2.4B |
| 总债务越低越好 | $140.0M | $2.5B |
| 股东权益账面价值 | $8.3B | $5.2B |
| 总资产 | $10.5B | $9.2B |
| 负债/权益比越低杠杆越低 | 0.02× | 0.48× |
8季度趋势，按日历期对齐
现金及短期投资CSGPHOLX
| Q4 25 | $1.6B | $2.4B | ||
| Q3 25 | $1.9B | $2.2B | ||
| Q2 25 | $3.6B | $1.9B | ||
| Q1 25 | $3.7B | $1.6B | ||
| Q4 24 | $4.7B | $2.0B | ||
| Q3 24 | — | $2.3B | ||
| Q2 24 | — | $2.4B | ||
| Q1 24 | — | $2.2B |
总债务CSGPHOLX
| Q4 25 | $140.0M | $2.5B | ||
| Q3 25 | $1.0B | $2.5B | ||
| Q2 25 | $1.0B | $2.5B | ||
| Q1 25 | $1.0B | $2.5B | ||
| Q4 24 | $1.0B | $2.5B | ||
| Q3 24 | $1.0B | $2.5B | ||
| Q2 24 | $1.0B | $2.5B | ||
| Q1 24 | $1.0B | $2.6B |
股东权益CSGPHOLX
| Q4 25 | $8.3B | $5.2B | ||
| Q3 25 | $8.6B | $5.0B | ||
| Q2 25 | $8.6B | $4.8B | ||
| Q1 25 | $8.6B | $4.6B | ||
| Q4 24 | $7.6B | $4.8B | ||
| Q3 24 | $7.5B | $5.1B | ||
| Q2 24 | $7.4B | $5.0B | ||
| Q1 24 | $7.3B | $4.8B |
总资产CSGPHOLX
| Q4 25 | $10.5B | $9.2B | ||
| Q3 25 | $10.8B | $9.0B | ||
| Q2 25 | $10.5B | $8.8B | ||
| Q1 25 | $10.4B | $8.5B | ||
| Q4 24 | $9.3B | $8.7B | ||
| Q3 24 | $9.1B | $9.2B | ||
| Q2 24 | $9.1B | $8.9B | ||
| Q1 24 | $9.0B | $8.7B |
负债/权益比CSGPHOLX
| Q4 25 | 0.02× | 0.48× | ||
| Q3 25 | 0.12× | 0.50× | ||
| Q2 25 | 0.12× | 0.52× | ||
| Q1 25 | 0.12× | 0.55× | ||
| Q4 24 | 0.13× | 0.53× | ||
| Q3 24 | 0.13× | 0.49× | ||
| Q2 24 | 0.14× | 0.51× | ||
| Q1 24 | 0.14× | 0.53× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $162.1M | $229.9M |
| 自由现金流经营现金流 - 资本支出 | $101.3M | $215.2M |
| 自由现金流率自由现金流/营收 | 11.3% | 20.5% |
| 资本支出强度资本支出/营收 | 6.8% | 1.4% |
| 现金转化率经营现金流/净利润 | 3.49× | 1.28× |
| 过去12个月自由现金流最近4个季度 | $123.0M | $1.0B |
8季度趋势，按日历期对齐
经营现金流CSGPHOLX
| Q4 25 | $162.1M | $229.9M | ||
| Q3 25 | $68.2M | $355.1M | ||
| Q2 25 | $146.5M | $343.3M | ||
| Q1 25 | $53.2M | $169.4M | ||
| Q4 24 | $94.6M | $189.3M | ||
| Q3 24 | $100.3M | $367.0M | ||
| Q2 24 | $58.1M | $405.8M | ||
| Q1 24 | $139.6M | $292.4M |
自由现金流CSGPHOLX
| Q4 25 | $101.3M | $215.2M | ||
| Q3 25 | $-5.5M | $341.4M | ||
| Q2 25 | $27.7M | $330.5M | ||
| Q1 25 | $-500.0K | $153.9M | ||
| Q4 24 | $25.2M | $172.5M | ||
| Q3 24 | $40.2M | $350.6M | ||
| Q2 24 | $-14.7M | $385.3M | ||
| Q1 24 | $-237.1M | $279.6M |
自由现金流率CSGPHOLX
| Q4 25 | 11.3% | 20.5% | ||
| Q3 25 | -0.7% | 32.5% | ||
| Q2 25 | 3.5% | 32.3% | ||
| Q1 25 | -0.1% | 15.3% | ||
| Q4 24 | 3.6% | 16.9% | ||
| Q3 24 | 5.8% | 35.5% | ||
| Q2 24 | -2.2% | 38.1% | ||
| Q1 24 | -36.1% | 27.5% |
资本支出强度CSGPHOLX
| Q4 25 | 6.8% | 1.4% | ||
| Q3 25 | 8.8% | 1.3% | ||
| Q2 25 | 15.2% | 1.3% | ||
| Q1 25 | 7.3% | 1.5% | ||
| Q4 24 | 9.8% | 1.6% | ||
| Q3 24 | 8.7% | 1.7% | ||
| Q2 24 | 10.7% | 2.0% | ||
| Q1 24 | 57.4% | 1.3% |
现金转化率CSGPHOLX
| Q4 25 | 3.49× | 1.28× | ||
| Q3 25 | — | 1.90× | ||
| Q2 25 | 23.63× | 1.76× | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.58× | 0.94× | ||
| Q3 24 | 1.89× | 2.05× | ||
| Q2 24 | 3.03× | 2.09× | ||
| Q1 24 | 20.84× | 1.72× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CSGP
| Co Star | $503.8M | 56% |
| Other | $283.0M | 31% |
| Loop Net | $94.7M | 11% |
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
